Form 4: Sanara MedTech CEO Ronald Nixon Receives Restricted Stock Grant
SEC Form 4 Filing
Sanara MedTech CEO Ronald T. Nixon received 10,812 shares of restricted stock on June 12, 2024, vesting on June 12, 2025, while also reporting indirect ownership through related entities.
Summary
- Ronald T. Nixon, CEO of Sanara MedTech Inc., filed a Form 4 on June 14, 2024, reporting changes in beneficial ownership.
- On June 12, 2024, Nixon acquired 10,812 shares of restricted stock granted by Sanara MedTech Inc. under the 2014 Omnibus Long-Term Incentive Plan.
- These shares will vest on June 12, 2025, contingent upon Nixon's continued service to the company.
- Nixon also reported indirect ownership of 2,452,731 shares through CGI Cellerate RX, LLC and 963,856 shares through FA Sanara, LLC.
- He disclaims beneficial ownership of these indirectly held shares except to the extent of his pecuniary interests.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to slightly positive.
Positives
- The grant of restricted stock aligns the CEO's interests with the long-term performance of the company.
- Continued service requirement for vesting ensures commitment from the CEO.
Future Outlook
The vesting of the restricted stock is contingent upon the reporting person providing certain services to the Company through June 12, 2025.
Industry Context
This filing is a routine disclosure of executive compensation and ownership changes, common in publicly traded companies. It provides transparency to investors regarding the alignment of management's interests with shareholder value.
Comparison to Industry Standards
- Restricted stock grants are a common form of executive compensation in the medical technology industry.
- Companies like Integra LifeSciences and Stryker also use similar long-term incentive plans to retain and motivate key executives.
- The vesting period of one year is relatively standard for restricted stock grants.
Stakeholder Impact
- Shareholders may view the restricted stock grant as a positive incentive for the CEO to drive long-term value.
- Employees may see this as a sign of stability and commitment from the company to its leadership.
Key Dates
| Date | Description |
|---|---|
| 06/12/2024 | Date of restricted stock grant and transaction date. |
| 06/12/2025 | Vesting date of the restricted stock. |
| 06/14/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.